Aurinia Pharmaceuticals: There's Still Time For Sales Growth
Portfolio Pulse from
Aurinia Pharmaceuticals' Lupkynis showed modest revenue growth from Q2'24 to Q3'24. The company is on track to meet its full-year 2024 revenue guidance of $210M-$220M, with $158.6M already reported. Q4 is expected to outperform Q3. Potential competitors include Roche and Biogen.
February 21, 2025 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aurinia Pharmaceuticals' Lupkynis showed modest revenue growth from Q2'24 to Q3'24. The company is on track to meet its full-year 2024 revenue guidance of $210M-$220M, with $158.6M already reported. Q4 is expected to outperform Q3.
Aurinia Pharmaceuticals is on track to meet its revenue guidance for 2024, with a strong Q4 expected. This positive outlook suggests a likely short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100